124I positron emission tomography versus 131I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer

Thyroid

Volumn 20, Issue 8, 2010, Pages 879-883

  Van Nostrand, Douglas ^a   Moreau, Shari ^a   Bandaru, Varalakshmi V ^a   Atkins, Frank ^a   Chennupati, Shyam ^a   Mete, Mihriye ^b   Burman, Kenneth ^a   Wartofsky, Leonard ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 124; IODINE 131;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER SCINTISCANNING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; THYROID CANCER; WHOLE BODY PET;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSTIC IMAGING; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; THYROID GLAND; THYROID NEOPLASMS; WHOLE BODY IMAGING;

EID: 77955285698     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.0430     Document Type: Article

References (12)

1. Phillips AF, Haybittle JL, Newbery GR 1960 Use of iodine-124 for the treatment of carcinoma of the thyroid. Acta Unio Int Contra Cancrum 16:1434-1438.
2. Atkins F, Van Nostrand D, Moreau S, Butler C, ONeil J, Burman KD, Wartofsky L 2008 Comparison of the blood biokinetics of I-124 and I-131 in patients with well-differentiated thyroid cancer (WDTC). J Nucl Med 49(Suppl): 323P.
3. Eschmann SM, Reischl G, Bilger K, Kuperferschlager J, Thelen MH, Dohmen BM, Bares R 2002 Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 29:760-767.
4. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, Robbins RJ, Larson SM 2004 Patient-specific dosimetry for 131-I thyroid cancer therapy using 124-I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45:1366-1372.
5. Freudenberg LS, Jentzen W, Gorges R, Petrich T, Marlowe RJ, Knust, J, Bockrish A 2007 124-I PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuclearmedizin 46:121-128.
6. Freudenberg LS, JentzenW,MarlowRJ, KoskaWW, Luster M, Bockisch A 2007 124-iodine positron emission tomography/ computed tomography dosimetry in pediatric patients with differentiated thyroid cancer. Exp Clin Endocrinol Diabetes 115:690-693.
7. Freudenberg LS, Antoch G, Jentzen W, Pink R, Knust J, Gorges R, Muller SP, Bockisch A, Debatin JF, Brandau W 2004 Value of 124-I PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 14:2092-2098.
8. Phan HTT, Jager PL, Paans AMJ, Plukker JTM, Sturkenboom MGG, Sluiter WJ, Wolffeenbuttel BHR, Dierckx RAJO, Links TP 2008 The diagnostic value of 124-I PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35:958-965.
9. Abdul-Fatah SB, Zamburlini M, Halders SGEA, Brans B, Teule GJJ, Kemerink GJ 2009 Identification of a shinethrough artifact in the trachea with 124-I PET-CT. J Nucl Med 50:909-911.
10. Schmidt D, Szikszai A, Linke R, Bautx W, Kuwert T 2008 Impact of 131-I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med 50:18-23.
11. Spanu A, Spolinas ME, Chessa F, Sanna D, Nuvoli S, Madeddu G 2009 131-I SPECT-CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med 50:184-190.
12. Alavi A, Basu S 2008 Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time? Eur J Nucl Med Mol Imaging 35:1554-1559.